Cyclerion Therapeutics Inc. (CYCN)
$3.16
$-0.05
(-1.56%)
As on 12-Jun-2026 12:42EDT
Market cap
$13 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.5
-
Face value
--
-
Shares outstanding
4,330,314
8 Years Aggregate
CFO
$-501.67 Mln
EBITDA
$-521.22 Mln
Net Profit
$-582.84 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cyclerion Therapeutics (CYCN)
| 148.8 | -0.9 | 121.0 | 5.0 | -10.1 | -47.5 | -- |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Cyclerion Therapeutics (CYCN)
| -60.6 | -3.8 | -74.5 | -61.9 | -43.8 | 12.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cyclerion Therapeutics (CYCN)
|
3.2 | 12.9 | 2.0 | -5.3 | -83.9 | -64.6 | -- | 2.0 |
| 283.0 | 40,461.0 | 4,286.9 | 577.2 | 9.8 | 88.2 | 76.3 | 37.6 | |
| 221.7 | 13,001.6 | 867.5 | 506.6 | -2.8 | -- | 23.9 | 23.8 | |
| 53.1 | 13,246.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 17.5 | 6.8 | |
| 131.2 | 16,655.9 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 179.4 | 29,936.9 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.3 | 4.9 | |
| 468.8 | 12,973.2 | 2,678.3 | 460.4 | 21.1 | 103.2 | 28.6 | 21.9 | |
| 614.6 | 66,620.0 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15.5 | 2.1 | |
| 540.6 | 23,340.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.3 | 4.0 | |
| 444.1 | 113,407.9 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
Shareholding Pattern
View DetailsAbout Cyclerion Therapeutics (CYCN)
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing... Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Read more
-
President
Dr. Regina Graul Ph.D.
-
President
Dr. Regina Graul Ph.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cyclerion Therapeutics (CYCN)
What is the current share price of Cyclerion Therapeutics Inc (CYCN) Today?
The share price of Cyclerion Therapeutics Inc (CYCN) is $3.16 (NASDAQ) as of 12-Jun-2026 12:42 EDT. Cyclerion Therapeutics Inc (CYCN) has given a return of -10.11% in the last 3 years.
What is the current PB & PE ratio of Cyclerion Therapeutics Inc (CYCN)?
Since, TTM earnings of Cyclerion Therapeutics Inc (CYCN) is negative, P/E ratio is not available.
The P/B ratio of Cyclerion Therapeutics Inc (CYCN) is 1.95 times as on 05-Jun-2026, a 52 discount to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.08
|
0.42
|
|
2024
|
-3.16
|
1.09
|
|
2023
|
-1.27
|
0.59
|
|
2022
|
-0.03
|
0.13
|
|
2021
|
-0.07
|
0.07
|
What is the 52 Week High and Low of Cyclerion Therapeutics Inc (CYCN)?
The 52-week high and low of Cyclerion Therapeutics Inc (CYCN) are Rs 8.48 and Rs 1.03 as of 13-Jun-2026.
What is the market cap of Cyclerion Therapeutics Inc (CYCN)?
Cyclerion Therapeutics Inc (CYCN) has a market capitalisation of $ 13 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cyclerion Therapeutics Inc (CYCN)?
Before investing in Cyclerion Therapeutics Inc (CYCN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.